Trial · NCT07882186
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
NCT07882186, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region. Trials, record NCT07882186. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882186
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
- NCT number
- NCT07882186
- Status
- Not yet recruiting
- Enrollment
- 1,605 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Vaccination Coverage Among Pregnant Women
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survey to Estimate Vaccination Coverage Against Pertussis, COVID-19, Seasonal Influenza, and RSV Infection Among Pregnant Women in Maternity Units in the Île-de-France Region. | Day 0 | Proportion of women vaccinated against pertussis, COVID-19, seasonal influenza, and RSV infection during pregnancy, by department type and by maternity unit type, and then estimate the proportion of vaccinated women across the entire Île-de-France region. |
| Secondary | Survey to determine the proportion of newborns who received RSV immunization through the administration of specific monoclonal antibodies | Day 0 | Proportion of newborns immunized against RSV through administration of specific monoclonal antibodies, born to mothers who were not vaccinated against RSV during pregnancy. |
| Secondary | Survey to assess knowledge of vaccination recommendations for pertussis, COVID-19, RSV, and seasonal influenza during pregnancy | Day 0 | Proportion of women aware of vaccination recommendations against pertussis, COVID-19, seasonal influenza, and RSV during pregnancy, and their sources of information. |
| Secondary | Questionnaire aimed at assessing the proportion of women who are aware of the recommendation for preventive immunization of newborns against RSV as well as identifying their main sources of information. | Day 0 | Proportion of women aware of the recommendation for pre-exposure immunization against RSV through administration of monoclonal antibodies-nirsevimab (Beyfortus®) or palivizumab (Synagis®)-to the newborn, and their sources of information. |
| Secondary | Questionnaire to Identify Factors Associated with Vaccination Against Pertussis, COVID-19, Seasonal Influenza, and RSV During Pregnancy | Day 0 | Vaccination status, knowledge of the listed infections, knowledge of vaccines, vaccination pathway, socio-demographic and socio-economic factors, category of healthcare professional providing pregnancy care. |
| Secondary | Questionnaire to identify factors associated with pre-exposure vaccination against RSV through the administration of monoclonal antibodies to newborns | Day 0 | Factors associated with pre-exposure immunization against RSV through administration of monoclonal antibodies-nirsevimab (Beyfortus®) or palivizumab (Synagis®)-to the newborn. |
| Secondary | Questionnaire to assess the acceptability of vaccination against pertussis, COVID-19, and seasonal influenza in the context of a future pregnancy. | Day 0 | Proportion of women who accepted vaccination against pertussis, COVID-19, and/or seasonal influenza during their pregnancy and who would accept the same vaccination(s) again in a future pregnancy. |
| Secondary | Questionnaire to assess the acceptability of various strategies for preventing RSV and bronchiolitis in newborns in the context of a future pregnancy or birth | Day 0 | Proportion of women whose newborn was immunized against RSV and who would accept either RSV immunization strategy in a future pregnancy/birth |
| Secondary | For women not vaccinated against pertussis during pregnancy, assess: • Reasons for non-vaccination against pertussis. • Acceptability of vaccination against pertussis during pregnancy and postpartum. • Barriers to vaccination against pertussis. | Day 0 | Proportion of women not vaccinated against COVID-19, seasonal influenza, and/or RSV during pregnancy who: i) would have accepted one or more of these vaccinations during that pregnancy, ii) would accept one or more of these vaccinations in a future pregnancy. |
| Secondary | Survey to determine the proportion of women who were not vaccinated against COVID-19, seasonal flu, and/or RSV during their pregnancy and who would have agreed or would agree to receive one or more of these vaccines | Day 0 | Proportion of women not vaccinated against COVID-19, seasonal influenza, and/or RSV during pregnancy who: I) would have accepted one or more of these vaccinations during that pregnancy, II) would accept one or more of these vaccinations in a future pregnancy. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882186
GET https://conductscience.org/api/trials/v1/NCT07882186/registered